Board Meeting5 Nov 2026, 06:15 pm
AstraZeneca Pharma India Board Approves Unaudited Results, Director Appointment
AI Summary
AstraZeneca Pharma India Ltd's Board of Directors met on November 5, 2026, approving the unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported total income of ₹7,442.2 million for the quarter and ₹14,362.4 million for the half-year. Key management changes were also approved, including the appointment of Mr. Krishnamurthy Narayanan Iyer as an Additional Director (Independent) and Mr. Atul Tandon as Chief Financial Officer. Additionally, Mr. Nitin Bindal's designation changed to Director - Biopharmaceuticals Business Unit, and Mr. Kumaran Krishnan was appointed Medical Director - Biopharmaceuticals Business Unit.
Key Highlights
- Board approved unaudited financial results for Q2 FY27.
- Total income for Q2 FY27 was ₹7,442.2 million.
- Mr. Krishnamurthy Narayanan Iyer appointed as Additional Director (Independent).
- Mr. Atul Tandon appointed as Chief Financial Officer.
- Several other senior management role changes and appointments were approved.
Price Impact
More from ASTRAZEN